![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
Public release date: 29-Nov-2011[ | E-mail |
Share ] Contact: Ron Najman
ron.najman@downstate.edu
718-270-2696
SUNY Downstate Medical Center
Event will take place Thursday, Dec. 1, 2011
Luther T. Clark, MD, FACC, will discuss preclinical drug discovery and development at SUNY Downstate Medical Center, Thursday, December 1, 2011. Dr. Clark's presentation will take place at 12:00 noon in the Health Science Education Building, Lecture Hall 1 A, 395 Lenox Road, Brooklyn, New York 11203.
Dr. Clark's remarks will cover how "Hit" molecules are identified and modified to become "Lead" compounds in the high-risk drug (nonpeptide) discovery process; the distinction between pharmacodynamics and pharmacokinetics of compounds; and the necessary efficacy and safety assessments that must occur before a molecule is considered a preclinical candidate.
Dr. Clark is the global director for scientific affairs (GDSA) for atherosclerosis, in the Office of the Chief Medical Officer at Merck. Before joining Merck in April 2007, he was chief of the Division of Cardiovascular Medicine and professor of clinical medicine at the SUNY Downstate Medical Center and Kings County Hospital Center, Brooklyn, New York. He was also director and principal investigator of the NIH-supported Brooklyn Health Disparities Research Center. He has authored more than 100 publications and edited the textbook, Cardiovascular Disease and Diabetes (McGraw-Hill 2007).
Dr. Clark is a fellow of the American College of Cardiology and the American College of Physicians, a past member of the Board of Directors of the Heritage Affiliate of the American Heart Association, and a past member of the New York State Cardiac Advisory Committee. He has served on a number of National Heart, Lung, and Blood Institute committees, including the CARDIA (Coronary Artery Risk Development in Young Adults) Review Board, the National Cholesterol Education Program (NCEP), and the NCEP's Expert Panels on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP I, ATP II, ATP III, and 2004 Update). Dr. Clark earned his bachelor of arts degree from Harvard College, Cambridge, Massachusetts, and his medical degree from Harvard Medical School, Boston, Massachusetts.
Merck Academy is an educational platform dedicated to sharing educational information with the academic and medical communities on subjects drawn from Merck's key areas of expertise. Merck Academy is a trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
###
SUNY Downstate Medical Center, founded in 1860, was the first medical school in the United States to bring teaching out of the lecture hall and to the patient's bedside. A center of innovation and excellence in research and clinical service delivery, SUNY Downstate Medical Center comprises a College of Medicine, Colleges of Nursing and Health Related Professions, a School of Graduate Studies, a School of Public Health, University Hospital of Brooklyn, and an Advanced Biotechnology Park and Biotechnology Incubator.
SUNY Downstate ranks ninth nationally in the number of alumni who are on the faculty of American medical schools. More physicians practicing in New York City have graduated from SUNY Downstate than from any other medical school.
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 29-Nov-2011[ | E-mail |
Share ] Contact: Ron Najman
ron.najman@downstate.edu
718-270-2696
SUNY Downstate Medical Center
Event will take place Thursday, Dec. 1, 2011
Luther T. Clark, MD, FACC, will discuss preclinical drug discovery and development at SUNY Downstate Medical Center, Thursday, December 1, 2011. Dr. Clark's presentation will take place at 12:00 noon in the Health Science Education Building, Lecture Hall 1 A, 395 Lenox Road, Brooklyn, New York 11203.
Dr. Clark's remarks will cover how "Hit" molecules are identified and modified to become "Lead" compounds in the high-risk drug (nonpeptide) discovery process; the distinction between pharmacodynamics and pharmacokinetics of compounds; and the necessary efficacy and safety assessments that must occur before a molecule is considered a preclinical candidate.
Dr. Clark is the global director for scientific affairs (GDSA) for atherosclerosis, in the Office of the Chief Medical Officer at Merck. Before joining Merck in April 2007, he was chief of the Division of Cardiovascular Medicine and professor of clinical medicine at the SUNY Downstate Medical Center and Kings County Hospital Center, Brooklyn, New York. He was also director and principal investigator of the NIH-supported Brooklyn Health Disparities Research Center. He has authored more than 100 publications and edited the textbook, Cardiovascular Disease and Diabetes (McGraw-Hill 2007).
Dr. Clark is a fellow of the American College of Cardiology and the American College of Physicians, a past member of the Board of Directors of the Heritage Affiliate of the American Heart Association, and a past member of the New York State Cardiac Advisory Committee. He has served on a number of National Heart, Lung, and Blood Institute committees, including the CARDIA (Coronary Artery Risk Development in Young Adults) Review Board, the National Cholesterol Education Program (NCEP), and the NCEP's Expert Panels on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP I, ATP II, ATP III, and 2004 Update). Dr. Clark earned his bachelor of arts degree from Harvard College, Cambridge, Massachusetts, and his medical degree from Harvard Medical School, Boston, Massachusetts.
Merck Academy is an educational platform dedicated to sharing educational information with the academic and medical communities on subjects drawn from Merck's key areas of expertise. Merck Academy is a trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
###
SUNY Downstate Medical Center, founded in 1860, was the first medical school in the United States to bring teaching out of the lecture hall and to the patient's bedside. A center of innovation and excellence in research and clinical service delivery, SUNY Downstate Medical Center comprises a College of Medicine, Colleges of Nursing and Health Related Professions, a School of Graduate Studies, a School of Public Health, University Hospital of Brooklyn, and an Advanced Biotechnology Park and Biotechnology Incubator.
SUNY Downstate ranks ninth nationally in the number of alumni who are on the faculty of American medical schools. More physicians practicing in New York City have graduated from SUNY Downstate than from any other medical school.
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2011-11/sdmc-dlt112911.php
cbsnews ufc on fox fight card florida marlins ncaa basketball boise state football boise state football jack and jill
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.